Name | Tasimelteon |
Synonyms | MA 1 VEC 162 BMS 214778 tasimelteon Tasimelteon tasimelteon impurity A (1R-trans)-N-[[2-(2,3-Dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide Tasimelteon (1R-trans)-N-[[2-(2,3-Dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide |
CAS | 609799-22-6 |
InChI | InChI=1/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1 |
Molecular Formula | C15H19NO2 |
Molar Mass | 245.32 |
Density | 1.145 |
Melting Point | 78 °C |
Boling Point | 442.6±24.0 °C(Predicted) |
Flash Point | 221.448°C |
Solubility | Chloroform (Slightly), Methanol (Slightly) |
Vapor Presure | 0mmHg at 25°C |
Appearance | Solid |
Color | White to Off-White |
pKa | 16.43±0.46(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.564 |
In vitro study | Tasimelteon (BMS-214778) has 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (K i =0.0692 nM and K i =0.17 nM in NIH-3T3 and CHO-K1 cells, respectively), than for the MT1 receptor (Ki=0.304 nM and Ki=0.35 nM, respectively). Tasimelteon has no appreciable affinity for more than 160 other pharmacologically relevant receptors and several enzymes. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 4.076 ml | 20.382 ml | 40.763 ml |
5 mM | 0.815 ml | 4.076 ml | 8.153 ml |
10 mM | 0.408 ml | 2.038 ml | 4.076 ml |
5 mM | 0.082 ml | 0.408 ml | 0.815 ml |
biological activity | Tasim elteon (BMS-214778) is a kind, selective dual melatonin receptor agonist (DMRA). The affinity of Tasimelteon for the MT2 receptor is 2.1-4.4 times that of the MT1 receptor. Tasimelteon is a circadian regulator with potential for Non-24 hour sleep/wake disorders (Non-24). |
Target | Value |
MT2 receptor () | 9.8(pKi) |
MT1 receptor () | 9.45(pKi) |